This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BNOX Bionomics (BNOX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Bionomics Stock (NASDAQ:BNOX) Get Bionomics alerts:Sign Up Key Stats Today's Range$0.25▼$0.2550-Day Range$0.24▼$0.3252-Week Range$0.18▼$0.94VolumeN/AAverage Volume6.12 million shsMarket Capitalization$4.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. Read More Receive BNOX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNOX Stock News HeadlinesBionomics Ltd – ADR trading halted, news pendingDecember 24, 2024 | markets.businessinsider.comBionomics Limited Receives Court Approval for Re-Domiciliation Scheme to Neuphoria Therapeutics Inc.December 18, 2024 | nasdaq.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.August 5 at 1:00 AM | Profits Run (Ad)Bionomics Ltd: Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-DomiciliationDecember 18, 2024 | finanznachrichten.deBionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-DomiciliationDecember 16, 2024 | globenewswire.comBionomics Ltd: Results of Scheme MeetingDecember 14, 2024 | finanznachrichten.deResults of Scheme MeetingDecember 12, 2024 | globenewswire.comBionomics Publishes the Positive Results from the Phase 2 ATTUNE Study of BNC210 in Patients with Post-Traumatic Stress Disorder in NEJM EvidenceDecember 9, 2024 | markets.businessinsider.comSee More Headlines BNOX Stock Analysis - Frequently Asked Questions When did Bionomics IPO? Bionomics (BNOX) raised $25 million in an initial public offering (IPO) on Thursday, December 16th 2021. The company issued 1,622,000 shares at $15.45 per share. What other stocks do shareholders of Bionomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include Meta Platforms (META), PayPal (PYPL), Intel (INTC), ChargePoint (CHPT), CRISPR Therapeutics (CRSP) and NVIDIA (NVDA). Company Calendar Today8/05/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BNOX CIK1191070 Webwww.bionomics.com.au Phone088-150-7400FaxN/AEmployeesN/AYear Founded1996Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.30 Quick Ratio3.30 Sales & Book Value Annual Sales$10 thousand Price / Sales446.82 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / Book0.19Miscellaneous Outstanding Shares17,654,000Free Float17,532,000Market Cap$4.47 million OptionableNot Optionable Beta0.26 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:BNOX) was last updated on 8/5/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
